InsiderTrades.com logo
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Keith A. Goldan net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Keith Goldan Biography and Net Worth

CFO of OptiNose
Keith Goldan joined Optinose in January 2017 as Chief Financial Officer. He brings to the Company more than 25 years of executive financial and operational leadership in biopharmaceutical and medical technology companies including CFO roles at private and public life sciences companies from early through commercial stage. Mr. Goldan most recently served as Senior Vice President and Chief Financial Officer at Fibrocell, a publicly held cell and gene therapy company, and of NuPathe, where he helped direct the sale of the specialty healthcare company to Teva in 2014. In these roles, Mr. Goldan led finance, IT, HR and corporate development teams and successfully raised capital though an IPO as well as multiple follow-on equity, rights, private placement and debt offerings.

Mr. Goldan’s experience also includes CFO roles at PuriCore (now Realm Therapeutics) and Biosyn as well as roles with ViroPharma and KPMG.

Mr. Goldan holds a Bachelor of Science (cum laude) in finance from the Robert H. Smith School of business at the University of Maryland and an MBA from the Wharton School at the University of Pennsylvania.

What is Keith A. Goldan's net worth?

The estimated net worth of Keith A. Goldan is at least $25,259.04 as of June 14th, 2024. Mr. Goldan owns 52,623 shares of OptiNose stock worth more than $25,259 as of November 23rd. This net worth approximation does not reflect any other assets that Mr. Goldan may own. Learn More about Keith A. Goldan's net worth.

How do I contact Keith A. Goldan?

The corporate mailing address for Mr. Goldan and other OptiNose executives is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. OptiNose can also be reached via phone at (267) 364-3500 and via email at [email protected]. Learn More on Keith A. Goldan's contact information.

Has Keith A. Goldan been buying or selling shares of OptiNose?

Keith A. Goldan has not been actively trading shares of OptiNose over the course of the past ninety days. Most recently, Keith A. Goldan sold 580 shares of the business's stock in a transaction on Thursday, December 16th. The shares were sold at an average price of $1.64, for a transaction totalling $951.20. Learn More on Keith A. Goldan's trading history.

Who are OptiNose's active insiders?

OptiNose's insider roster includes Victor Clavelli (Insider), Keith Goldan (CFO), Ramy Mahmoud (COO), Michael Marino, III (Insider), and Peter Miller (CEO). Learn More on OptiNose's active insiders.

Are insiders buying or selling shares of OptiNose?

In the last year, insiders at the sold shares 11 times. They sold a total of 295,529 shares worth more than $374,251.18. The most recent insider tranaction occured on July, 17th when CAO Anthony J Krick sold 6,845 shares worth more than $7,803.30. Insiders at OptiNose own 2.7% of the company. Learn More about insider trades at OptiNose.

Information on this page was last updated on 7/17/2024.

Keith A. Goldan Insider Trading History at OptiNose

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/16/2021Sell580$1.64$951.20View SEC Filing Icon  
3/15/2021Sell2,304$3.92$9,031.6891,347View SEC Filing Icon  
9/23/2020Buy2,500$3.90$9,750.00View SEC Filing Icon  
See Full Table

Keith A. Goldan Buying and Selling Activity at OptiNose

This chart shows Keith A Goldan's buying and selling at OptiNose by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

OptiNose Company Overview

OptiNose logo
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Read More

Today's Range

Now: $0.48
Low: $0.39
High: $0.48

50 Day Range

MA: $0.69
Low: $0.34
High: $0.91

2 Week Range

Now: $0.48
Low: $0.32
High: $2.10

Volume

1,285,310 shs

Average Volume

771,487 shs

Market Capitalization

$72.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Urgent: This election is rigged
From Porter & Company   |   Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.